We developed a reversed-phase chromatographic procedure for detecting benzodiazepines and other drugs in serum. A liquid-liquid extraction step with hexane/ethyl acetate isolates the drugs from serum; absolute recoveries are generally >85%. Reconstituted extracts are chromatographed on a 4-urn (particle size) C18 column; 14 drugs and an internal standard (flunitrazepam) are separated in 8 mm. Peak detection, purity checking, and identification are performed with a computerized photodiode-array detector. Run-to-run imprecision (CV) for many benzodiazepines is <3%. In a study of 126 specimens from Emergency Department patients, the procedure showed excellent agreement with a gas-chromatographic method involving either mass-spectrometric or flame-ionization detection. This single procedure provides rapid and accurate detection, quantification, and confirmation of benzodiazepines in serum.
procedures for benzodiazepines have been reported recently (e.g., [4] [5] [6] [7] [8] [9] . These procedures involve single-wavelength ultraviolet detection. Implicit in such singlewavelength chromatographic analyses is the assumption that only the retention time of a peak is needed to identify a compound and that the identified peak is composedof only one compound. The specificity of such analyses is thus largely dependent on the chromatographic separation itself. As shorter and more sensitive analyses for multiple drugs are attempted, however, chromatographic selectivity may not be sufficient to ensure an accurate analysis, and interferences result (10-12). Changes in chromatographic selectivity as a column ages also can lead to interferences. Singlewavelength chromatographic analyses are not necessarily specific, and they do not meet the spirit of the general rule of clinical toxicology and drug-screening laboratories; i.e., confirm all positive results by obtaining alternative chemical information.
More-specific detectors for liquid chromatography include mass spectrometry (13) and photodiode-array absorbance detectors (PDAs) (14). An electrochemical detector has been used in a forensic benzodiazepine assay (15). We investigated the potential of PDAs for benzodiazepine analysis (16) (17) (18) (19) by designing a rapid LC/PDA method and comparing this method with GCIMS.
Materialsand Methods

Apparatus
The LC system consisted of a Model M45 pump, a U6K injector, and a 990+ Photodiode Array Detector! APC IV computer (with software version 5.02). The analytical columns used were packed with Novapack C18 (4-.an average particle size, 3.9-mm i.d. Table 1 , it is considereda confirmed positive and is then quantified. The library-search routine and spectralmatching algorithm used by the PDA have been described by Hill et al. (20) . A perfect match of an unknown to a library spectrum will have a "fit" of 1000.
Unknowns that differ to a greater degree from a particular library spectrum will have progressively lower fit numbers.
For drug quantification, one obtains the peak height ratio between the confirmed peak and the internal standard and compares this ratio with that obtained for a working standard solution carried through the entire (9) . Hexane/ethyl acetate was chosen as the extraction solvent because it provided >85% absolute recoveries for many benzodiazepines and gave relatively clean chromatographic baselines at 214 and 230 nm when several drug-free sera were analyzed. Also, use of this solvent allows a rapid analysis because the supernate in the extraction is analyzed, the solvent can be vortex-mixed with serum without gel formation, and no centrifugation is required after the mixing step. Extracts of drug-free serum typically have only two significant peaks in the 2-to 8-mm interval (at about 2.0 and 3.8 mm). These peaks have distinct ultraviolet spectra and are usually <0.0015 A.
To optimize the separation, we investigated ternary mobile phases of pH 6.4 phosphate buffer, acetonitrile, and methanol. The addition of methanol to the mobile phase proved particularly useful. This modifier aided the separation of an unknown peak (seen in most sera) from demoxepam and assisted the separation of other compounds that co-eluted when acetonitrile was the only modifier used and lidocaine. The behavior of this potential interferent demonstrates the need to confirm peak identity, despite well-controlled benzodiazepine chromatography and the extensive interference study shown in Table 2 . In this mobile phase, most benzodiazepines exhibit absorbance maxima in the 220-235-nm range. We chose a lower wavelength (214 nm) to monitor the chromatographic separation because the benzodiazepines have a relatively high molar absorptivity there and because the lower wavelength offers the potential for detecting other drugs that lack appreciable absorptivity above 230 nm (lidocaine, glutethimide, etc.). At 214 nm, the PDA typically exhibits peak-to-peak noise of about 0.00004-0.00006 A. We estimated the sensitivityof the method to detect various benzodiazepines (see Table 1) by calculation with the peak height of an extracted control solution and assuming the minimum detectable peak height to be 0.00018 A (three times the noise). Sensitivity can be improved by injecting larger sample volumes, but extra column band broadening of the earlier-eluting benzodiazepines becomes excessive.
Confirming the identity of a peak in a sample depends on retention time and how well the spectrum of the peak matches that of a compound in the PDA library. The degree of fit to the PDA library depends primarily on (a) the prevailing instrument signal-to-noise ratio and (b) whether the peak is co-eluted with other compounds. The first factor decreases the degree of fit as lower concentrations of a compound are analyzed. As an example, injections of 14, 35, and 140 nmol of oxazepam per liter produced fits of 957, 976, and 995 (average of five injections each). The second factor will also lower the fit of a compound, depending on the co-eluting compound(s) and the ratios of their concentrations to the peak of interest. Analyses of standard drug solutions at the concentrations listed in Table 3 consistently give fits greater than 940; we use this fit value to declare a match (i.e., to confirm the identity of a peak). In our experience, the concentration of a compound necessary to produce a fit value >940 is usually at least threefold the concentration that can be detected at 214 nm. The method's run-to-mn precision data are shown in Table 3 . Quantitative imprecision (CV) is <3% for most of the drugs of interest. Run-to-run precision of the spectral match is also shown in Table 3 . The spectra of these compounds appear not to be changed by slight changes in mobile phase, several mobile-phase preparations having been used during the spectral-match precision study.
We performed a split-sample correlation study between this LCIPDA method and a GC method involving either mass-spectrometric or flame-ionization detection (23). We collected 503 samples from patients presenting to our Emergency Department. An emergency toxicology screen had been requested and performed by GC on each of these samples. We selected without conscious bias 63 samples judged negative by the comparison method for the drugs listed in Table 3 and analyzed them by the LC/PDA method; all were found negative by LC/PDA. Sixty-three samples positive for the drugs listed in Table  3 Table 3 do not necessarily reflect the limits of the LC/PDA method; rather, we based these values on the detection limits of both methods and on clinical needs.
DIscussion
A 45-mmgradient LC/PDA procedure for benzodiazepines has been described, but method-comparison studies were not reported (24) . Two groups have compared LC plus FDA with alternative methods of analysis for benzodiazepines in urine (25, 26) . The excellent agreement with the comparison methods reported here for serum samplessupportsour belief that PDA detection is specific enough to be the confirmation step in clinical toxicology analysis. A potential problem with PDA detection is that an interfering substance can co-elute with the drug of interest, thus altering a peak's spectrum and preventing a match with the drug's library spectra. Is is also theoretically possible that multiple compounds could co-elute such that the impure peak could mimic the spectrum of a benzodiazepine. This problem did not occur in the comparison study, and such co-elutions are probably rare events. Mathematical techniques such as rank annihilation analysis have been described (27) that can resolve peaks of interest from interferences during most co-elution events; we did not use such techniques in this study.
This laboratory uses this procedure for emergency drug screening 24 h a day, with the following modifications from the reported procedure: Sample and extraction solvent volumes are reduced by 50%, the internal standard concentration is halved, and 100 pL of mobile phase is used for reconstitution. A 20-s vortex-mixing of the extraction mixture followed by 1 mm of centrifugation is used instead of 5 mm of mechanical shaking and 5 mm of centrifugation. With these modifications, a completed chromatogram can be available in <20 mm after the start of the procedure. Assay sensitivity and specificity are not changed. Run-to-mn imprecision increases, but is still generally <4%. The rapid turnaround time and the accuracy of this method make it suitable for clinical toxicology, allowing detection, confirmation, and quantification of many benzodiazepine drugs quickly with a single method.
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